{
    "nct_id": "NCT05180799",
    "official_title": "A Phase 1/2 Study of BA3071 in Patients With Solid Tumors",
    "inclusion_criteria": "* Patients must have measurable disease.\n* Age ≥ 18 years\n* CLTA-4 blocking-antibody naïve\n* Adequate renal function\n* Adequate liver function\n* Adequate hematological function\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Patients must have single or any combination of the following mutations: KRAS, STK11, KEAP1 and/or PD-L1 TPS <1%\n* Patients must be eligible for surgery (NSCLC Stage IIB-IIIA only)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients must not have clinically significant cardiac disease.\n* Patients must not have known non-controlled CNS metastasis.\n* Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as well as known or suspected allergy or intolerance to any agent given during this study.\n* Patients must not have had major surgery within 4 weeks before first BA3071 administration.\n* Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.\n* Patients must not be women who are pregnant or breast feeding.",
    "miscellaneous_criteria": ""
}